Anit-il-23 antibiodies

An IL-23, antibody technology, applied in the direction of antibody, anti-animal/human immunoglobulin, anti-cytokine/lymphokine/interferon immunoglobulin, etc., can solve the high-affinity neutralizing human IL-23 antibody Issues not made public

Inactive Publication Date: 2008-08-20
ELI LILLY & CO
View PDF0 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Although human IL-23 antibodies have been reported previously, high-affinity neutralizing human IL-23 antibodies that recognize specific epitopes on the p19 subunit have not been published

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0125] IL-23 inhibition assay

[0126] Based on the ability of IL-23 to stimulate mouse splenocytes to secrete IL-17, inhibition of IL-23 activity was detected using a mouse splenocyte assay. Antibodies of the invention were compared with MAb3A8 and the commercially available mouse monoclonal antibody MAB1290 (R&D Systems).

[0127] The basic protocol is as follows: spleens are removed from 1BALB / c or C57BL / 6 mice, splenocytes are harvested, and single-cell suspensions are prepared. Splenocytes were killed with complete RPMI (containing 1% non-essential amino acids, 1% sodium pyruvate, 2.5mM HEPES, 1% L-glutamic acid, 0.00035% 2-mercaptoethanol, 1% penicillin / streptomycin, 10% heat Live serum FCS and 50ng / mL human IL-2 (Andy Biotechnology)) were washed and resuspended. Then splenocytes were seeded in a 96-well culture plate at 500,000 cells / well, with a volume of 100 μl.

[0128]Human IL-23 (Andy Biotechnology) at a concentration of 10 pM was pre-incubated with 3-fold seria...

Embodiment 2

[0134] Neutralization of human IL-23

[0135] Injection of human IL-23 into mice together with IL-2 stimulates splenocytes to produce mouse IL-17. Neutralizing antibodies directed against the IL-23p19 subunit blocked this IL-17 stimulation, as demonstrated by ex vivo IL-17 production readout in an in vivo mouse model as follows.

[0136] C57BL / 6 mice were sensitized by injection of mIL-2 22 hours before stimulation with mouse IL-2 (mIL-2) plus human IL-23 (hIL-23). Mice were injected with a high affinity humanized antibody of the invention or an isotype-matched (IgG4) control antibody 2 hours before stimulation with mIL-2 and hIL-23.

[0137] Then set the following groups:

[0138] At time point 0, mIL-2 (5 μg) alone or mIL-2 (5 μg) plus human IL-23 (10 μg) was injected intraperitoneally (i.p.)

[0139] At 7 hours, mIL-2 (10 μg) alone or mIL-2 (10 μg) plus human IL-23 (10 μg) was injected intraperitoneally

[0140] At 23 hours, mIL-2 (5 μg) alone or mIL-2 (5 μg) plus human...

Embodiment 3

[0146] binding affinity

[0147] The affinity between MAb3A8 and the antibody of the present invention was detected by BIAcore measurement system (Table 3). BIAcore TM is an automated biosensor system that measures molecular interactions (Karlsson et al. (1991) J. Immunol. Methods 145:229-240). In these experiments, antibodies were captured to BIAcore at low density TM on the surface of the chip. Coupling of protein A to carboxymethyl (CM5) BIAcore using active amino groups of ethyldimethylaminopropylcarbodiimide (EDC) TM Flow cell for the sensor chip. Protein A was diluted in sodium acetate buffer, pH 4.5, and immobilized to the flow cell of a CM5 chip using EDC to generate 1000 response units. Unreacted sites were blocked with ethanolamine. A flow rate of 60 μl / min was used. Multiple conjugations were performed by injecting 10 μl of 2 μg / mL antibody solution of the invention per cycle, followed by injections of decreasing concentrations of human IL-23 (e.g., 1500, 750...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease.

Description

field of invention [0001] The invention belongs to the field of medicine, in particular to the field of anti-interleukin 23 (IL-23) monoclonal antibody. The present invention more particularly relates to neutralizing anti-IL-23 monoclonal antibodies for use in the treatment of autoimmune diseases. Background of the invention [0002] IL-23 is believed to be a cytokine that is critical for the activation of the large number of inflammatory cells required to induce chronic inflammation. IL-23 has distinct but complementary functions to IL-12, a 70 kDa heterodimeric cytokine consisting of covalently linked p40 and p35 subunits. IL-23 is composed of the same p40 subunit as IL-12, but this subunit is covalently paired with the p19 subunit (Langrish et al. Immunological Reviews 202:96-105, 2004). [0003] Furthermore, IL-23 has been implicated in memory / pathogenic T cell responses by promoting the secretion of the pro-inflammatory cytokine IL-17 by activated T cells. There is i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/24A61P25/00A61K39/395
Inventor C·B·白德尔S·W·布赖特C·D·迪金森K·K·基克利D·M·马奎斯A·P·瓦塞罗特
Owner ELI LILLY & CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap